Methadone induction doses: Are our current practices safe?

Journal of Addictive Diseases

Volumn 25, Issue 3, 2006, Pages 5-13

  Srivastava, Anita ^a   Kahan, Meldon ^a  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

Guidelines; Induction dose; Literature search; Methadone; Overdose

Indexed keywords

METHADONE;

CLINICAL PRACTICE; DOSE RESPONSE; DRUG OVERDOSE; DRUG SAFETY; DRUG USE; EVIDENCE BASED PRACTICE; HUMAN; MORTALITY; PRACTICE GUIDELINE; PRESCRIPTION; REVIEW;

AGE FACTORS; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG MONITORING; DRUG TOXICITY; GUIDELINES; GUIDELINES AS TOPIC; HEROIN DEPENDENCE; HUMANS; METHADONE; NARCOTICS; PATIENT EDUCATION; PATIENT EDUCATION AS TOPIC; RISK FACTORS;

EID: 33748461349     PISSN: 10550887     EISSN: 15450848     Source Type: Journal    
DOI: 10.1300/J069v25n03_02     Document Type: Review

References (41)

1. College of Physicians and Surgeons of Ontario, CfAaMH, Ontario College of Pharmacists. Methadone Maintenance Guidelines. 2001.
2. Sanchez-Carbonell X, Seus, L. Ten-year survival analysis of a cohort of heroin addicts in Catalonia: the EMETYST project. Addiction 2000; 95:941-8.
3. Frischer M, Goldberg D, Rahman M, Berney L. Mortality and survival among a cohort of drug injectors in Glasgow, 1982-1994. Addiction 1997; 92:419-27.
4. Caplehorn JR, Dalton MS, Haldar F, Petrenas AM, Nisbet JG. Methadone maintenance and addicts' risk of fatal heroin overdose. Subst Use Misuse 1996; 31:177-96.
5. Bell J, Zador D. A risk-benefit analysis of methadone maintenance treatment. Drug Saf 2000; 22:179-90.
6. Zanis DA, Woody GE. One-year mortality rates following methadone treatment discharge. Drug Alcohol Depend 1998; 52:257-60.
7. Buster MC, van Brussel GH, van den Brink W. An increase in overdose mortality during the first 2 weeks after entering or re-entering methadone treatment in Amsterdam. Addiction 2002; 97:993-1001.
8. Cooper GA, Seymour A, Cassidy MT, Oliver JS. A study of methadone in fatalities in the Strathclyde Region, 1991-1996. Med Sci Law 1999; 39:233-42.
9. Caplehorn JR, Drummer OH. Mortality associated with New South Wales methadone programs in 1994: lives lost and saved. Med J Aust 1999; 170:104-9.
10. Seymour A, Black M, Jay J, Cooper G, Weir C, Oliver J. The role of methadone in drug-related deaths in the west of Scotland. Addiction 2003; 98:995-1002.
11. Zador D, Sunjic S. Deaths in methadone maintenance treatment in New South Wales, Australia 1990-1995. Addiction 2000; 95:77-84.
12. Valmana A, Oyefeso A, Clancy C, Ghodse H. Methadone-related deaths: data from 18 coroners' jurisdictions in England. Med Sci Law 2000; 40:61-5.
13. Vormfelde SV, Poser W. Death attributed to methadone. Pharmacopsychiatry 2001; 34:217-22.
14. Wolff K, Rostami-Hodjegan A, Shires S, Hay AW, Feely M, Calvert R, Raistrick D, Tucker GT. The pharmacokinetics of methadone in healthy subjects and opiate users. Br J Clin Pharmacol 1997; 44:325-34.
15. Karch SB, Stephens BG. Toxicology and pathology of deaths related to methadone: retrospective review. West J Med 2000; 172:11-4.
16. Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet 2002; 41:1153-93.
17. Corkery JM, Schifano F, Ghodse AH, Oyefeso A. The effects of methadone and its role in fatalities. Hum Psychopharmacol 2004; 19:565-76.
18. Wolff K. Characterization of methadone overdose: clinical considerations and the scientific evidence. Ther Drug Monit 2002; 24:457-70.
19. Strang J, Sheridan J. Effect of national guidelines on prescription of methadone: analysis of NHS prescription data, England 1990-2001. BMJ 2003; 327:321-2.
20. Caplehorn J. Deaths in the first two weeks of maintenance treatment in NSW in 1994: identifying cases of iatrogenic methadone toxicity. Drug and Alcohol Review 1998; 17:9-17.
21. Harding-Pink D. Methadone: one person's maintenance dose is another's poison. Lancet 1993; 341: 665-6.
22. Drummer OH, Opeskin K. Methadone toxicity causing death in ten subjects starting on a methadone maintenance program. Am J Forensic Med Pathol 1992; 13:346-50.
23. Baden MM. Methadone related deaths in New York City. Int J Addict 1970; 5:489-98.
24. Mikolaenko I, Robinson CA, Jr., Davis GG. A review of methadone deaths in Jefferson County, Alabama. Am J Forensic Med Pathol 2002; 23:299-304.
25. Caplehorn JR, Drummer OH. Fatal methadone toxicity: signs and circumstances, and the role of benzodiazepines. Aust N Z J Public Health 2002; 26:358-62; discussion 362-3.
26. DAWN. The DAWN Report: Methadone-Involved Deaths in Eight Metropolitan Areas: 1997-2001, 2004.
27. Borron SW, Monier C, Risede P, Baud FJ. Flunitrazepam variably alters morphine, buprenorphine, and methadone lethality in the rat. Hum Exp Toxicol 2002; 21:599-605.
28. White JM, Irvine RJ. Mechanisms of fatal opioid overdose. Addiction 1999; 94:961-72.
29. Tarumi Y, Pereira J, Watanabe S. Methadone and fluconazole: respiratory depression by drug interaction. J Pain Symptom Manage 2002; 23:148-53.
30. Herrlin K, Segerdahl M, Gustafsson LL, Kalso E. Methadone, ciprofloxacin, and adverse drug reactions. Lancet 2000; 356:2069-70.
31. Hamilton SP, Nunes EV, Janal M, Weber L. The effect of sertraline on methadone plasma levels in methadone-maintenance patients. Am J Addict 2000; 9:63-9.
32. Iribarne C, Berthou F, Baird S, Dreano Y, Picart D, Bail JP, Beaune P, Menez JF. Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol 1996; 9:365-73.
33. Cairns J. Methadone-related deaths in Ontario. Toronto: Ontario Coroner's Office, 2000.
34. Drug Misuse and Dependence-Guidelines on Clinical Management: Department of Health, Scottish Office Department of Health, Welsh Office, Department of Health and Social Services, Northern Ireland, 1999.
35. Graham AW, Schultz TK, Mayo-Smith MF, Ries RK, Wilford, BB. Principles of Addiction Medicine. ASAM Publication, Chevy Chase, MD, 2003.
36. Buesekom I, Martin YI. A review of recent advances in knowledge about methadone maintenance treatment, RAND Policy Research, Santa Monicas, CA, 2001.
37. Verster A., BE. European Methadone Guidelines. 2000.
38. Pirnay, S, Borron SW, Giudicelli CP, Tourneau J, Baud FJ, Ricordel I. A critical review of the causes of death among post-mortem toxicological investigations: analysis of 34 buprenorphine-associated and 35 methadone-associated deaths. Addiction 2004; 99:978-88.
39. Repchinsky C. Compendium of Pharmaceutical and Specialties: The Canadian drug reference for health professionals. Ottawa: Canadian Pharmacists Association, 2003.
40. Caplehorn JR, Bell J. Methadone dosage and retention of patients in maintenance treatment. Med J Aust 1991; 154:195-9.
41. Caplehorn J. More on Iatrogenic methadone toxicity, Letter. Drug and Alcohol Review 1998; 17:467-8.